[pubmed] Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impa

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 2983
Enregistré le : 31 mai 2020 09:57
3
Zodiaque :
Âge : 20
Contact :
    Linux Chrome

[pubmed] Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impa

Message par RSS-Bot »


Eur J Neurol. 2021 Jun 3. doi: 10.1111/ene.14951. Online ahead of print.

ABSTRACT

BACKGROUND AND PURPOSE: Myasthenia gravis (MG) patients could be a vulnerable group in the pandemic era of Coronavirus 2019 (COVID-19) mainly due to respiratory muscle weakness, older age, and long-term immunosuppressive treatment. We aimed to define factors predicting the severity of COVID-19 in MG patients and risk of MG exacerbation during COVID-19.

METHODS: We evaluated clinical features and outcomes after COVID-19 in 93 MG patients.

RESULTS: Thirty-five patients (38%) had severe pneumonia and we recorded 10 deaths (11%) due to COVID-19. Higher forced vital capacity (FVC) values tested before COVID-19 were shown as protective against severe infection CI 95% (0.934- 0.98) as well as good control of MG measured by quantified myasthenia gravis score CI95% (1.047 - 1.232). Long term chronic corticosteroid treatment worsened the course of COVID-19 in MG patients CI95% (1.784-111.43) and this impact was positively associated with dosage (p-value 0.005). Treatment using azathioprine CI95% (0.448 - 2.935), mycophenolate mofetil CI95% (0.91 - 12.515) and ciclosporin CI95% (0.029 - 2.212) did not influence the course of COVID-19. MG patients treated by rituximab had a high risk of death caused by COVID-19 CI95% (3.216 - 383.971). Exacerbation of MG during infection was relatively rare (15%) and was not caused by remdesivir, convalescent plasma or favipiravir CI95% (0.885 - 10.87).

CONCLUSIONS: As the most important predictors of severe COVID-19 in MG patients we identified unsatisfied condition of MG with lower FVC, previous long-term corticosteroid treament especially in higher doses, older age, the presence of cancer, and recent rituximab treatment.

PMID:34080271 | DOI:10.1111/ene.14951


Source: https://pubmed.ncbi.nlm.nih.gov/3408027 ... 0&v=2.14.4
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur association.amis-modo@myasthenie.com


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »